TUR-007

TUR-007 is an investigational small-molecule drug candidate being developed for Canavan disease, a rare pediatric leukodystrophy caused by deficiency of aspartoacylase and resulting in accumulation of the neurotoxic metabolite N-acetylaspartate (NAA) and subsequent myelin degeneration in the brain.[1][7][11] Preclinical data indicate that TUR-007 is designed to reduce or modulate NAA production, thereby targeting a key upstream pathological mechanism of Canavan disease with the goal of preserving myelin integrity and improving neurological outcomes, and it has been advanced through sponsored research collaborations including work at the University of Toledo.[1][7][11]